2021
DOI: 10.1016/j.cllc.2021.03.006
|View full text |Cite
|
Sign up to set email alerts
|

Biomarkers of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Beyond PD-L1

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(6 citation statements)
references
References 93 publications
0
6
0
Order By: Relevance
“…Prospective studies with proper control of the patient condition, type of immunotherapy used, type of concurrent treatment modalities, and adequate follow-up period will be required to answer this question. How 3D PD-L1 score correlates with other predictive biomarkers for immunotherapy response, such as tumor mutation burden or microsatellite instability [ 20 ] is another crucial question. Importantly, all 33 surgical resection specimens we studied consisted mainly of adenocarcinoma.…”
Section: Discussionmentioning
confidence: 99%
“…Prospective studies with proper control of the patient condition, type of immunotherapy used, type of concurrent treatment modalities, and adequate follow-up period will be required to answer this question. How 3D PD-L1 score correlates with other predictive biomarkers for immunotherapy response, such as tumor mutation burden or microsatellite instability [ 20 ] is another crucial question. Importantly, all 33 surgical resection specimens we studied consisted mainly of adenocarcinoma.…”
Section: Discussionmentioning
confidence: 99%
“…Data of serum measurements were visualized and statistically analysed with GraphPad Prism 9 (GraphPad Software, San Diego, California, USA) and SPSS 26.0 (IBM, Ehningen, Germany). Data were statistically analysed under REMARK criteria (12). Progression-free survival (PFS) time was calculated from the date of medication start until the last date of contact or progression of the disease under RECIST 1.1 criteria (24).…”
Section: Statistical Analysesmentioning
confidence: 99%
“…Likewise, other researched biomarker candidates have not been proven to be helpful in clinical settings. Only in a small subset of cancers mismatch repair /microsatellite instability and tumour mutations can serve as biomarkers for predicting immune checkpoint inhibitors efficacy (12).…”
Section: Introductionmentioning
confidence: 99%
“…As the most common type of lung cancer, non-small cell lung cancer (NSCLC) faces difficulties that over 50% of patients are diagnosed with advanced disease initially, for which the 5-year survival is nearly 5% (2). Moreover, the recommended standard treatment, chemotherapy and/or radiotherapy, offers generally modest efficacy for metastatic NSCLC patients.…”
Section: Introductionmentioning
confidence: 99%